Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beijing Tiantan Biological ProductsSHSE:600161 +2.56%68 Return-on-Tangible-Equity is 5.15% as of Mar. 2026, which is 65% below its 10-year median of 14.87. GuruFocus rates SHSE:600161 with a GF Score™ of 68/100 and a GF Value™ of ¥23.05 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,199 Biotechnology companies, Beijing Tiantan Biological Products ranks better than 86.66% on this metric.
The historical rank and industry rank for Beijing Tiantan Biological Products's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:600161'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 10.09 Med: 14.87 Max: 43.69
Current: 10.09
During the past 13 years, Beijing Tiantan Biological Products's highest Return-on-Tangible-Equity was 43.69%. The lowest was 10.09%. And the median was 14.87%.
SHSE:600161's Return-on-Tangible-Equity is ranked better than 86.66% of 1199
companies
in the Biotechnology industry
Industry Median: -42.4
vs SHSE:600161: 10.09
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Beijing Tiantan Biological Products Return-on-Tangible-Equity Related Terms
Beijing Tiantan Biological Products Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600161 vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Beijing Tiantan Biological Products's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Tiantan Biological Products Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beijing Tiantan Biological Products's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Beijing Tiantan Biological Products's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 5.15% mean?
Beijing Tiantan Biological Products (SHSE:600161) has a Return-on-Tangible-Equity of 5.15% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Beijing Tiantan Biological Products and its competitors. This is 65% below median its historical median of 14.87. Over the past decade, Beijing Tiantan Biological Products' Return-on-Tangible-Equity has ranged from 10.09 to 43.69. According to the industry distribution chart, Beijing Tiantan Biological Products ranks #160 out of 1199 companies in the Biotechnology industry, placing it in the top 13.3%.
Is Beijing Tiantan Biological Products' Return-on-Tangible-Equity too high?
Beijing Tiantan Biological Products' current Return-on-Tangible-Equity of 5.15% is 65% below median its 10-year median of 14.87. Over the past 10 years, this metric has ranged from a low of 10.09 to a high of 43.69. Based on the distribution chart, Beijing Tiantan Biological Products ranks #160 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Beijing Tiantan Biological Products has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Tiantan Biological Products' Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Tiantan Biological Products ranks #160 out of 1199 companies for Return-on-Tangible-Equity. This places Beijing Tiantan Biological Products in the top 13% of its industry — outperforming the majority of peers. Historically, Beijing Tiantan Biological Products' own Return-on-Tangible-Equity has ranged from 10.09 to 43.69 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Beijing Tiantan Biological Products and its competitors. Beijing Tiantan Biological Products's current Return-on-Tangible-Equity is 5.15%, which is 65% below median its own 10-year median of 14.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tiantan Biological Products stock overvalued right now?
Based on GuruFocus' analysis, Beijing Tiantan Biological Products (SHSE:600161) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥23.05, compared to a current price of ¥12.84 — trading 44.3% below its estimated fair value. The current Return-on-Tangible-Equity is 5.15%, which is 65% below median its 10-year median of 14.87. Beijing Tiantan Biological Products' overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Beijing Tiantan Biological Products (SHSE:600161), the current Return-on-Tangible-Equity is 5.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Tiantan Biological Products (SHSE:600161) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Tiantan Biological Products stock appears to be undervalued.
The current stock price of ¥12.84 is trading 44.3% below its estimated GF Value™ of ¥23.05.
GuruFocus considers Beijing Tiantan Biological Products to be Significantly Undervalued.
Key valuation signals for SHSE:600161:
Return-on-Tangible-Equity: 5.15% (65% below median its 10-year median of 14.87)
GF Value™: ¥23.05 vs. price of ¥12.84 (44.3% below fair value)
No single metric tells the full story. See the SHSE:600161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Tiantan Biological Products Business Description
Beijing Tiantan Biological Products Corp Ltd uses healthy human plasma and specifically immunized human plasma as raw materials and adopts genetic recombination technology to develop and produce blood products and engage in the blood product business. The company's main products include human albumin, human immunoglobulin (pH4) for intravenous injection, human hepatitis B immunoglobulin, human immunoglobulin, human rabies immunoglobulin, human histamine immunoglobulin, and others.
68GF Score
Get the complete analysis for SHSE:600161
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600161 has been successfully added to your 
